Benjamin Weide

Summary

Country: Germany

Publications

  1. ncbi request reprint Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19-IL2 Results in Sustained Clinical and Systemic Immunologic Responses
    Benjamin Weide
    Authors Affiliations Departments of Dermatology, Center of Dermato Oncology and
    Cancer Immunol Res 2:668-78. 2014
  2. pmc Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy
    Benjamin Weide
    Department of Dermatology, University Medical Center, Tubingen, Germany German Cancer Research Center dkfz, Heidelberg, Germany German Cancer Consortium DKTK, Heidelberg, Germany
    PLoS ONE 8:e81624. 2013
  3. doi request reprint Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma
    Diana Meckbach
    Division of Dermatooncology, Department of Dermatology, University Medical Center Tübingen, Tubingen, Germany
    PLoS ONE 9:e86194. 2014
  4. pmc Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumour
    Benjamin Weide
    Center for Dermatooncology, Department of Dermatology, University Medical Center, Tuebingen, Germany
    PLoS ONE 8:e66953. 2013
  5. pmc Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosis
    Benjamin Weide
    Department of Dermatology, University Medical Center, Tubingen, Germany
    PLoS ONE 8:e63137. 2013
  6. pmc Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis
    B Weide
    Department of Dermatology, Center for Dermatooncology, University Medical Center, Liebermeisterstrasse 25, Tubingen 72076, Germany
    Br J Cancer 107:422-8. 2012
  7. doi request reprint Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis
    Benjamin Weide
    University Medical Center, University of Tubingen, Tubingen, Germany
    J Clin Oncol 30:1835-41. 2012
  8. doi request reprint Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up
    Benjamin Weide
    Department of Dermatology, Center of Dermatooncology, University of Tubingen, Liebermeisterstr 25, 72076, Tubingen, Germany
    Cancer Immunol Immunother 60:487-93. 2011
  9. doi request reprint High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma
    Benjamin Weide
    Department of Dermatology, Center of Dermato Oncology, University of Tuebingen, Tuebingen, Germany
    Cancer 116:4139-46. 2010
  10. doi request reprint Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients
    Benjamin Weide
    Department of Dermatology, Division of Dermatooncology, University of Tubingen, Tubingen, Germany
    J Immunother 32:498-507. 2009

Collaborators

Detail Information

Publications26

  1. ncbi request reprint Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19-IL2 Results in Sustained Clinical and Systemic Immunologic Responses
    Benjamin Weide
    Authors Affiliations Departments of Dermatology, Center of Dermato Oncology and
    Cancer Immunol Res 2:668-78. 2014
    ..Finally, we recorded encouraging data about the progression time to distant metastases and overall survival. Cancer Immunol Res; 2(7); 668-78. ©2014 AACR. ..
  2. pmc Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy
    Benjamin Weide
    Department of Dermatology, University Medical Center, Tubingen, Germany German Cancer Research Center dkfz, Heidelberg, Germany German Cancer Consortium DKTK, Heidelberg, Germany
    PLoS ONE 8:e81624. 2013
    ..This study aimed to analyse the impact of S100B, lactate dehydrogenase (LDH) and the type of treatment on survival in advanced patients receiving systemic treatment...
  3. doi request reprint Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma
    Diana Meckbach
    Division of Dermatooncology, Department of Dermatology, University Medical Center Tübingen, Tubingen, Germany
    PLoS ONE 9:e86194. 2014
    ..A potential role of the mutational status as a prognostic factor especially in this subgroup needs to be investigated in larger studies...
  4. pmc Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumour
    Benjamin Weide
    Center for Dermatooncology, Department of Dermatology, University Medical Center, Tuebingen, Germany
    PLoS ONE 8:e66953. 2013
    ....
  5. pmc Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosis
    Benjamin Weide
    Department of Dermatology, University Medical Center, Tubingen, Germany
    PLoS ONE 8:e63137. 2013
    ....
  6. pmc Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis
    B Weide
    Department of Dermatology, Center for Dermatooncology, University Medical Center, Liebermeisterstrasse 25, Tubingen 72076, Germany
    Br J Cancer 107:422-8. 2012
    ..Established prognostic factors are of limited value to predict long-term survival and benefit from metastasectomy in advanced melanoma. This study aimed to identify prognostic factors in patients with distant metastasis...
  7. doi request reprint Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis
    Benjamin Weide
    University Medical Center, University of Tubingen, Tubingen, Germany
    J Clin Oncol 30:1835-41. 2012
    ..To analyze the prognostic relevance of circulating T cells responding to NY-ESO-1, Melan-A, MAGE-3, and survivin in patients with melanoma with distant metastasis...
  8. doi request reprint Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up
    Benjamin Weide
    Department of Dermatology, Center of Dermatooncology, University of Tubingen, Liebermeisterstr 25, 72076, Tubingen, Germany
    Cancer Immunol Immunother 60:487-93. 2011
    ..Furthermore, the intratumoral IL-2 treatment seemed to be associated with increased complete and partial responses in subsequent chemotherapies...
  9. doi request reprint High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma
    Benjamin Weide
    Department of Dermatology, Center of Dermato Oncology, University of Tuebingen, Tuebingen, Germany
    Cancer 116:4139-46. 2010
    ..The objectives of the current study were to confirm those results in a larger cohort and to identify patient or regimen characteristics associated with response...
  10. doi request reprint Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients
    Benjamin Weide
    Department of Dermatology, Division of Dermatooncology, University of Tubingen, Tubingen, Germany
    J Immunother 32:498-507. 2009
    ....
  11. ncbi request reprint Plasmid DNA- and messenger RNA-based anti-cancer vaccination
    Benjamin Weide
    Department of Dermatology, University of Tubingen, Liebermeisterstrasse 25, Tubingen, Germany
    Immunol Lett 115:33-42. 2008
    ..Combining optimized MNAV formulations and parallel adjuvant treatments could allow to turn MNAV-based vaccines into efficient anti-tumor immunotherapies in humans...
  12. doi request reprint Results of the first phase I/II clinical vaccination trial with direct injection of mRNA
    Benjamin Weide
    Department of Dermatology, Institute for Cell Biology, University of Tubingen, Germany
    J Immunother 31:180-8. 2008
    ..However, a demonstration of clinical effectiveness of direct injection of copy mRNA for antitumor immunotherapy was not shown in this study and must be evaluated in subsequent trials...
  13. ncbi request reprint Melanoma staging: facts and controversies
    Andrea Forschner
    Center for Dermato Oncology, Department of Dermatology, University Hospital Tubingen, 72076 Tubingen, Germany
    Clin Dermatol 28:275-80. 2010
    ..The risk of recurrence or tumor progression is very high in stage IV patients, and their management is individualized...
  14. ncbi request reprint Excision guidelines and follow-up strategies in cutaneous melanoma: Facts and controversies
    Ulrike Leiter
    Center of Dermato Oncology, Department of Dermatology, University of Tuebingen, Liebermeisterstr 25, 72076 Tuebingen, Germany
    Clin Dermatol 28:311-5. 2010
    ..Whereas the treatment for primary melanoma is accepted world wide, follow-up strategies for melanoma patients are discussed controversially, and so far, no international consensus has been reached...
  15. ncbi request reprint Incisional biopsy and melanoma prognosis: Facts and controversies
    Annette Pflugfelder
    Center for Dermatooncology, Department of Dermatology, University Hospital Tubingen, Liebermeisterstr 25, 72076 Tubingen, Germany
    Clin Dermatol 28:316-8. 2010
    ..Incisional biopsies of malignant melanoma do not negatively influence prognosis. Complete excision of primary melanoma is still the recommended standard of care and is a precondition for accurate histopathologic diagnosis...
  16. pmc Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma
    Annette Pflugfelder
    Department of Dermatology, Center for Dermatooncology, University Hospital Tuebingen, Tuebingen, Germany
    PLoS ONE 6:e16882. 2011
    ..Based on previous promising experiences within a clinical trial involving carboplatin and paclitaxel a series of advanced metastatic melanoma patients were treated with this combination...
  17. ncbi request reprint BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy
    Diana Meckbach
    Division of Dermatooncology, Department of Dermatology, University Medical Center Tübingen, Tubingen, Germany
    PLoS ONE 9:e89218. 2014
    ..The impact of BRAF tumor mutations on the natural course of disease of melanoma patients is controversial...
  18. pmc Prognosis of sentinel node staged patients with primary cutaneous melanoma
    Otmar Elsaesser
    Center for Dermatooncology, Department of Dermatology, and Central Malignant Melanoma Registry of the German Dermatological Society, Eberhard Karls University of Tuebingen, Tuebingen, Germany
    PLoS ONE 7:e29791. 2012
    ....
  19. doi request reprint A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma
    Thomas K Eigentler
    Department of Dermatology, University Medical Center, Tubingen, Germany
    Clin Cancer Res 17:7732-42. 2011
    ..5 million international units (Mio IU) IL2 equivalents. In this study, safety and clinical activity of L19-IL2 in combination with dacarbazine were assessed in patients with metastatic melanoma...
  20. doi request reprint Vemurafenib reverses immunosuppression by myeloid derived suppressor cells
    Bastian Schilling
    Department of Dermatology, University Hospital, University Duisburg Essen, Essen, Germany
    Int J Cancer 133:1653-63. 2013
    ..In vitro as well as in vivo, Vemurafenib inhibits the generation of human moMDSCs. Thus, Vemurafenib decreases immunosuppression in patients with advanced melanoma, indicating its potential as part of future immunotherapies. ..
  21. doi request reprint Melanoma of unknown primary is correctly classified by the AJCC melanoma classification from 2009
    Anne F Pfeil
    Center of Dermato Oncology, Eberhard Karls University, Tuebingen, Germany
    Melanoma Res 21:228-34. 2011
    ..Patients with MUP can be classified according to AJCC, which presented as the strongest prognostic factor. From a management perspective it is important to notice that the majority of MUP were classified as stage III...
  22. ncbi request reprint Imiquimod in the treatment of extensive recurrent lentigo maligna
    Anne Kamin
    Department of Dermatology, Skin Cancer Program, Eberhard Karls University, Tuebingen, Germany
    J Am Acad Dermatol 52:51-2. 2005
    ..Clinically and histologically, a complete clearing of the lesion was observed after treatment. Topical treatment with imiquimod seems to be effective and safe in lentigo maligna...
  23. pmc Hsps are up-regulated in melanoma tissue and correlate with patient clinical parameters
    Christopher Shipp
    Tubingen Ageing and Tumour Immunology Group, Section for Transplantation Immunology, Department of Internal Medicine II, Centre for Medical Research, University of Tubingen, Waldhornlestr 22, 72072 Tubingen, Germany
    Cell Stress Chaperones 18:145-54. 2013
    ..This study provides further evidence for the importance of hsps in melanoma and for their use as therapeutic targets and biomarkers, but larger-scale follow-up studies are required to confirm these results...
  24. ncbi request reprint Early disseminated borreliosis with multiple erythema migrans and elevated liver enzymes: case report and literature review
    Frauke Benedix
    Department of Dermatology, Eberhard Karls University Tubingen
    Acta Derm Venereol 87:418-21. 2007
    ..Dermatologists should keep in mind that early disseminated borreliosis can present with multiple erythema migrans and hepatitis...
  25. doi request reprint No evidence of viral genomes in whole-transcriptome sequencing of three melanoma metastases
    Magdalena Feldhahn
    Center for Bioinformatics, University of Tubingen, Tubingen, Germany Division of Dermatooncology, Department of Dermatology, University of Tubingen, Tubingen, Germany Medical Genetics, University of Tubingen, Tubingen, Germany
    Exp Dermatol 20:766-8. 2011
    ..This renders it less likely that viruses are frequently involved in melanoma induction. A larger number of melanoma transcriptome sequencings are required to rule out viruses as a relevant pathogen...
  26. pmc Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells
    Daniela Beck
    Division of Dermatologic Oncology, Department of Dermatology, University of Tubingen, 72076 Tubingen, Germany
    Sci Signal 6:ra7. 2013
    ..Thus, thapsigargin or other inducers of ER stress may be useful in combination therapies to overcome vemurafenib resistance...